Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of G-CSF-induced bone pain with naproxen, hydroxyzine, or Noscough syrup in cancer patients
IRCT20231227060538N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of naproxen and hydroxyzine in ostealgia (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Incidence and severity of bone pain due to PEG G-CSF. Started Mar 2024; status: completed.
02
Drugs
naproxenhydroxyzine
03
Conditions
ostealgia
Beyond the preview
Go deeper on IRCT20231227060538N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231227060538N1.